Kerfuffle Over Marijuana Claim

A pro-pot group airs an ad stating marijuana is “less toxic” than alcohol, but a federal science agency disputes the assertion.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, HUPU2Marijuana law reform has been in the air lately. Last November, Colorado and Washington voted to legalize recreational weed use in their states, and Illinois recently became the latest state to legalize the drug for use as a medicine. In a speech at the American Bar Association’s annual meeting this month, US Attorney General Eric Holder announced that the federal government would no longer seek harsh mandatory minimum sentences for drug offenders that had no ties to gangs, violence, or trafficking—though he drew the ire of medical marijuana proponents for failing to mention the drug specifically once during the speech. Now, the National Institute on Drug Abuse (NIDA) has weighed in on what appears to be a rising tide of pro-marijuana sentiment.

In response to an advertisement sponsored by the pro-pot group Marijuana Policy Project, which called marijuana “less toxic” than alcohol, NIDA wrote in an e-mail to watchdog group PolitiFact: "Claiming that marijuana is less toxic than alcohol cannot be substantiated since each possess their own unique set of risks and consequences for a given individual." PolitiFact, which fact-checks claims made by politicians, pundits, and special interest groups, surmised the claim that marijuana is less toxic than alcohol was “mostly true,” citing numbers from the Centers for Disease Control’s (CDC) National Center for Health Statistics. According to the CDC, more than 41,000 deaths were tied to alcohol in 2010 (almost 16,000 attributed to alcoholic liver disease and more than 25,000 to alcohol-related accidents and homicides), while ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies